{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:30:23Z","timestamp":1794292223795,"version":"4.9.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The JCR Grant for Promoting Research for Precision Medicine in Rheumatoid Arthritis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To elucidate the prevailing concerns by analysing the shifts in clinical profiles and therapeutic outcomes of patients with RA from 2003 to 2022, and offer guidelines to refine future treatment approaches.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Utilizing our registry data, we conducted an analysis of the patient background and biennial variations in the clinical remission rate 1\u2009year post-initiation of biological\/targeted synthetic DMARDs (b\/tsDMARDs) in patients with RA in Phase II. We investigated the determinants of remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study registered 2916 patients. Over time, the patient demographics evolved, characterized by an increase in the average age of patients, earlier initiation of b\/tsDMARDs, and variability in the rate of concomitant use of MTX. The remission rate, as measured by the Clinical Disease Activity Index (CDAI), consistently rose from 2003 to 2013, then declined after reaching its peak in 2013. By 2021, it had returned to the same level observed in 2009. The findings of the multivariate analysis indicated that the factors contributing to CDAI remission after 1\u2009year included the administration of MTX at a dosage of 10\u2009mg\/week or higher, the absence of concomitant glucocorticoid use, low disease activity, a low HAQ Disability Index score, and the utilization of Janus kinase (JAK) inhibitors. Specifically, since 2011, the use of MTX has declined alongside rising average serum creatinine levels. Additionally, the utilization of JAK inhibitors has rapidly decreased since 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Despite advancements in treatment and early intervention strategies, the clinical remission rate for RA has not shown consistent improvement. Factors contributing to this include reduced use of MTX.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf246","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:11:17Z","timestamp":1747123877000},"page":"5023-5030","source":"Crossref","is-referenced-by-count":7,"title":["Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9693-9263","authenticated-orcid":false,"given":"Satoshi","family":"Kubo","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-9356","authenticated-orcid":false,"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Sakai","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Ueno","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Todoroki","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]},{"name":"Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurie","family":"Satoh-Kanda","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-145X","authenticated-orcid":false,"given":"Ippei","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]},{"name":"Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"2025090315130561700_keaf246-B1","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025090315130561700_keaf246-B2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025090315130561700_keaf246-B3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025090315130561700_keaf246-B4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/s10165-007-0626-3","article-title":"Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis","volume":"17","author":"Koike","year":"2007","journal-title":"Mod Rheumatol"},{"key":"2025090315130561700_keaf246-B5","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/annrheumdis-2015-207784","article-title":"Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching","volume":"75","author":"Kubo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090315130561700_keaf246-B6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clim.2018.03.018","article-title":"Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; adjusted with propensity score matching","volume":"191","author":"Kubo","year":"2018","journal-title":"Clin Immunol"},{"key":"2025090315130561700_keaf246-B7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","article-title":"Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study","volume":"74","author":"Tanaka","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025090315130561700_keaf246-B8","first-page":"63","article-title":"Ageing population and landscape of rheumatoid arthritis treatment in Japan","volume":"11","author":"Kubo","year":"2024","journal-title":"EMJ Rheumatol"},{"key":"2025090315130561700_keaf246-B9","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025090315130561700_keaf246-B10","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025090315130561700_keaf246-B11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2025090315130561700_keaf246-B12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/14397595.2013.854051","article-title":"Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study","volume":"24","author":"Kubo","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2025090315130561700_keaf246-B13","first-page":"834","article-title":"Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study","volume":"34","author":"Kubo","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025090315130561700_keaf246-B14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2025090315130561700_keaf246-B15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40780-016-0069-0","article-title":"Genetic polymorphisms of enzyme proteins and transporters related to methotrexate response and pharmacokinetics in a Japanese population","volume":"2","author":"Hashiguchi","year":"2016","journal-title":"J Pharm Health Care Sci"},{"key":"2025090315130561700_keaf246-B16","year":"2019"},{"key":"2025090315130561700_keaf246-B17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2025090315130561700_keaf246-B18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/mr\/roae064","article-title":"Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case post-marketing surveillance study","volume":"35","author":"Okamoto","year":"2025","journal-title":"Mod Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf246\/63166601\/keaf246.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/5023\/63166601\/keaf246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/5023\/63166601\/keaf246.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:13:14Z","timestamp":1756926794000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/9\/5023\/8129581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,13]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf246","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,13]]}}}